Microsoft word - varenicline nhs ce.doc
Is varenicline cost-effective enough to be funded by the NHS now?
John Stapleton, Kings College London - Institute of Psychiatry 8/12/2006
These are promising times for those treating smokers in the UK services with the
launch of an effective new smoking cessation medication after many years when
there has been little new to offer those unable to quit with existing treatments.
ASH have issued a preliminary guide to varenicline (1) and The Cochrane
Collaboration have completed a comprehensive efficacy review to be published
early in the 2007 (Cochrane Library 2007, Issue 1) (2). This note is intended to
supplement these by providing an estimate of the cost effectiveness of
varenicline in the NHS. Background
In September varenicline (Champix, Pfizer) was given a marketing license to aid
smoking cessation by the European Medicines Agency (3). Following the launch
of varenicline in the UK on December 5th PCTs and others will need to decide if
they fund varenicline. Whether varenicline is viewed as sufficiently effective and
safe for the NHS need not be in doubt, given the extensive license review
undertaken by the EMEA and the FDA in the US. As a new drug it will be subject
to post-marketing surveillance and will be part of the MHRA “yellow card” safety
reporting scheme (4). No unexpected side effects have come to light after
several months of use in the USA.
On the important issue of cost-effectiveness to the NHS, NICE guidance on
varenicline will probably not be issued until the late Spring of 2007 (5). However,
unless their previous very positive recommendations on existing smoking
cessation treatments are completely reversed, they are likely to conclude that
varenicline is also highly cost-effective and will recommend it to the NHS. How cost-effective is varenicline?
Cost-effectiveness models for smoking cessation treatments are quite
complicated, involving lifetime effectiveness projections, lifetime health gains,
economic discounting, and costs in practice (6). In the 2002 NICE assessment of
the cost-effectiveness of NRT and bupropion (Zyban, GSK) all these elements
were considered. Fortunately, a cost-effectiveness estimate for varenicline
sufficiently accurate for NHS funding decisions need not involve detailed
statistics and economics. One need only use an established NHS cost-
effectiveness figure for bupropion and modify it for differences in cost and
efficacy between varenicline and bupropion. Below are the simple calculations. (1) The NICE upper limit is about £20-30K to gain a life year in the NHS
Although NICE do not publish the figure, it is accepted that they typically
recommend a treatment to the NHS if the cost is less than about £20 - £30K for
each life year gained (LYG).
(2) Bupropion gains a life year for about £1100.
In 2002 NICE recommended bupropion and NRT to the NHS and cited them as,
“among the most cost effective of all healthcare interventions” (7). Quoting
several alternative figures they concluded with a general LYG figure at UK
discount rates of “below £2,000 per life year gained”. This figure being at least 10
– 15 times below the NICE “bar” they probably did not need to be more precise.
The average for NHS treatments is about £15k to gain a life year. More precise
details were given in the parallel NHS Health Technology Assessment (8). It
gave the following LYG estimates:
Bupropion SR £1100 (range £640 - £1500)
NRT £1700 (range £1000 - £2400) (3) In practice varenicline will cost about 60% more than bupropion
A12-week course of varenicline will cost £164, compared to about £120 - £150
for NRT and £80 for the full 8 week course of bupropion. In practice, many
smokers starting treatment will not return to take the full course and this changes
the actual cost to the NHS. The packaging of varenicline (2-week or 4-week
packs) allows it to be prescribed according to the same regime that NICE
recommended for NRT: 2 weeks, 2 weeks, 4 weeks, 4 weeks. Bupropion is
prescribed in 4 week packs. Assuming that 70%, 50% and 40% of patients return
for additional medication after 2, 4, and 8 weeks respectively, gives an average
cost to treat a smoker with varenicline of about £96. For bupropion the average
cost would be about £60, and for NRT about £79. In practice varenicline will
therefore cost about 60% more than bupropion and 20% more than NRT. (4) Varenicline is about twice as effective as bupropion
The efficacy of varenicline and bupropion have been directly compared in two
large well-designed multicentre trials, and one less well designed trial where
previous users of bupropion were allowed to take part (2). In the two better
designed trials bupropion increased the 12 month continuous success rate by 6%
above that for counseling alone and varenicline increased it by 13%. The specific
efficacy of varenicline was therefore about twice that of bupropion.
[This figure from direct comparisons of the two treatments in the same trial can
be almost exactly replicated by comparing how much more effective than
placebo each treatment is across all the placebo controlled trials that have only
included one or other treatment. Cochrane (9) calculate an odds ratio of 2.00 for
bupropion and 3.22 from the four varenicline trials (2) (note: the ASH document
omits two trials and therefore cites a slightly lower figure of 2.85). The increases
in 12 month continuous abstinence rates were about 8% and 14% for bupropion
and varenicline, respectively. The numbers needed to treat were 13 and 7 for
bupropion and varenicline, respectively. Hence, to achieve each long term
success attributable to bupropion one might need to treat almost twice as many
smokers as with varenicline]. (5) Varenicline cost-effective estimate
Combining figures from (2), (3) and (4) gives a cost-effectiveness estimate for
varenicline, based on the NHS estimate for bupropion:
Varenicline cost per life year gained = (£1,100 x 1.6)/2.0 ~ £900.
In the above, the NHS cost per LYG figure of £1,100 for bupropion is multiplied
by 1.6 because varenicline costs about 60% more and is divided by 2 because
on current evidence it is about twice as effective. The difference between the
LYG figures for bupropion and varenicline is within the margin of error of these
calculations and too small to be of any practical significance.
The figure above shows that varenicline is about 20 - 30 times more cost
effective than the NICE upper limit for the NHS. Therefore, if PCTs are currently
funding bupropion and NRT prescriptions they should also fund varenicline
prescriptions on at least an equal basis. Even if NICE produces a different figure,
based possibly on a different discount rate than used in 2002 for bupropion and
NRT they will still give positive guidance on varenicline. If they do use a different
model then their previous estimates for bupropion and NRT will also need to
change, leaving the relative cost effectiveness of the 3 treatments the same. Varenicline for 24 weeks?
For the calculation above, the assumption has been that varenicline is prescribed
for 12 weeks. As mentioned in the ASH document, the license allows it to be
prescribed for an additional 12 weeks for those not smoking at 12 weeks. There
is only one published trial testing the efficacy of the additional 12 weeks of
treatment. One trial is usually not enough to form a good evidence base, even
when it is a large multinational trial. Hence, it is far more difficult to anticipate
NICE guidance on the additional 12 weeks.
Although the effect of the extra 12 weeks treatment was shown to be statistically
significant in the trial, the additional clinical benefit was about half that achieved
by the initial course of 12 weeks in the four 12-week treatment trials (6.7% vs
14% additional 1 year quitters). The trial did not identify a sub-group of smokers
for whom the additional 12 weeks treatment was more beneficial. The estimate of
cost per life year gained will therefore be about twice the figure for the initial 12
weeks, in the region of £2,000. This is still well below the NICE limit for the NHS
and should therefore receive a positive recommendation. However, if smoking
cessation medication budgets are restricted and demand for varenicline is high,
there will be a health benefit from treating 2 smokers for 12 weeks, rather than 1
smoker for 24 weeks at the same cost.
Potential conflict of Interest
JS has acted on an ad-hoc basis as an adviser/consultant to several
organisations with an interest in smoking cessation, including NICE, DH, MRC
and several manufacturers and developers of smoking cessation products and
technologies. The current note was undertaken as an independent piece of work
and was not supported or prompted by any organisation.
(1) Varenicline. Guidance for health professionals on a new prescription-only
stop smoking medication. ASH, London November 2006.
(2) Cahill K, Stead L, Lancaster T. Nicotine receptor partial agonists for smoking
cessation. Cochrane Library: (Due for release 2007 Issue 1)
(6) Stapleton et. al. Prescription of transdermal nicotine patches for smoking
cessation in general practice: evaluation of cost-effectiveness. Lancet. 1999 Jul
17;354 (9174): 210-5.
(7) http://www.nice.org.uk/guidance/TA39 at 4.3.1.
(8) Health Technology Assessment 2002; Vol. 6: No. 16.
(9) JR Hughes, LF Stead, T Lancaster. Antidepressants for smoking cessation.
Cochrane Database of Systematic Reviews 2006 Issue 4.
Canadian Federation of Students House of Commons Standing Committee on Finance August, 2001 123456789012345678901234567890121234567890123456789012345678901212345678901234567890123456789012123456789012345678901234567890123456789012345678901234567890121234567890123456789012345678901212345678901234567890123456789012123456789012345678901234567890123456789012345678901234567890121234567890
The Cochran School of Nursing Guide to APA Citation Style - 6th Edition Examples of sources Journals (DOI) system “A Digital Object Identifier (DOI) is a unique alphanumeric string assigned by a registration agency (the International DOI Foundation) to identify content and provide a persistent link to its location on the internet”. (APA 6th ed., p. 189, 2010). Inc